Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Imc12

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05061784Completed

Routine Transcervical Thymectomy in MEN-1 Patients

NCT00965250Phase 2Completed

Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy

Showing all 2 trials

Research Network

Common Treatments

  • Imc121
  • Routine Thymectomy Which Has Been Performed1

Active Sponsors

  • National Cancer Institute (NCI)1
  • National University Health System, Singapore1

Top Investigators

Related Conditions

  • Thymoma1
  • Multiple Endocrine Neoplasia Type 1 Men11
  • Thymic Carcinoma1
  • Thymic Neuroendocrine Tumors1

Activity Timeline